Bruker Corporation (BRKR) Stock: Price, Forecast & Analyst Target
Bruker Corporation (BRKR) — MoonshotScore 59/100 (Fair band), calculated Nov 18, 2026. Price $62.10 (-1.83%), as of the Nov 19, 2026 trading session; market cap $9.48B. Expected results Feb 11, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 56.77× (cash as of Sep 30, 2026) · expected results Feb 11, 2027
Bruker Corporation · BRKR · NASDAQ · Healthcare · Medical - Devices
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered): Bruker sells scientific instruments, diagnostic platforms, nanoscale and semiconductor metrology tools, plus superconducting materials and systems; it is much broader than a conventional medical-device manufacturer. The case depends on whether this product-heavy portfolio can turn growing sales into dependable margins and cash generation while debt remains far above cash.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Bruker (BRKR)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet, weak growth and a full valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Fading; Momentum: Surging.
- quarterly revenue $874M (Q3 FY2026, quarter ended Sep 2026)
- EPS beat 6 of the last 8 reports
- Altman Z 2.89 · Piotroski F 5
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 57 | Fair | |
| 58 | Fair | |
| 58 | Fair | |
| 58 | Fair | |
| 59 | Fair | |
| 59 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $62.10 | |
| Change on the day | -1.83% | |
| 52-week range | $32.37–$68.98 | |
| Market capitalisation | $9.48B | — |
| Shares traded on the day | 1.84M | |
| Beta (volatility vs the S&P 500) | 1.26 | |
| Dividends per share (last 12 months) | $0.20 | |
| Dividend yield (last 12 months) | 0.33% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
While the lead times on these orders are longer than most of our life science tools, we expect to see these semi orders convert into revenue mostly in fiscal year 2027 and some in fiscal year 2028.
Frank Laukien · Statement from
We now expect currency to be approximately neutral to reported revenue for fiscal year 2026 after the recent strengthening of the U.S. dollar. We continue to expect non-GAAP operating margin expansion of 250-300 basis points year over year, largely driven by our cost-saving actions.
Gerald Herman · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Bruker (BRKR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Bruker (BRKR), and what does it report?
Short answer · as of
Laboratories, drug and biomarker researchers, microbiology users, semiconductor customers, and advanced-research facilities buy Bruker systems for measurement, identification, imaging, process control, and materials work.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Revenue therefore reflects shipments across capital equipment, analytical tools, diagnostics, superconducting materials, and related services rather than a narrow stream of patient-facing medical devices.
Reporting groups the business around life-science instrumentation, nanoscale tools, and energy and superconducting technologies. Product sales dominate the disclosed revenue split, leaving reported sales sensitive to instrument demand and customer delivery schedules.
What do the latest results show for Bruker (BRKR)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $874M.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Latest revenue improved from the preceding period and the comparable period, while gross profit also rose. Yet operating and net results swung into loss, and operating cash flow turned negative, so the sales improvement did not translate into accounting or cash profitability.
The reported-versus-estimated earnings series cleared consensus even though the income statement showed a loss; those measures need to remain separate. Management says semiconductor customer delivery requirements shifted planned revenue into a later period and expects near-term margin pressure before higher volume and favorable mix support a rebound.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $874.00M Sep 30, 2026
- Latest quarter · R&D
- $92.00M Sep 30, 2026
- Latest quarter · SG&A
- $226.50M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$91.00M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $874.00M | $92.00M | $226.50M | −$91.00M |
| Jun 30, 2026 | $838.50M | $94.30M | $238.90M | −$65.30M |
| Mar 31, 2026 | $823.40M | $101.30M | $242.10M | $45.00M |
| Dec 31, 2025 | $977.20M | $99.60M | $247.20M | $111.80M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $874.00M Nov 4, 2026
- Latest report · revenue estimate
- $865.16M Nov 4, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 4, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 4, 2026 | $874.00M | $865.16M | $0.5600 | $0.4190 |
| Aug 4, 2026 | $838.50M | $853.57M | $0.4900 | $0.3849 |
| May 6, 2026 | $823.40M | $795.62M | $0.3100 | $0.2300 |
| Feb 12, 2026 | $977.20M | $962.26M | $0.5900 | $0.6500 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $874M | -$112M | -$0.81 (diluted) |
| Q2 FY2026 | $839M | -$52M | -$0.41 (diluted) |
| Q1 FY2026 | $823M | $14M | $0.02 (diluted) |
| Q4 FY2025 | $977M | $26M | $0.10 (diluted) |
What are the financial strengths and risks for Bruker (BRKR)?
Short answer
Cash and short-term investments were $167.00M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $118.20M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Bruker retains meaningful gross profit and current assets exceed current liabilities, but the stricter near-cash liquidity measure falls short of full coverage. Annual sales have expanded while net income deteriorated into loss, showing that commercial growth has not protected the bottom line.
Debt greatly exceeds cash and short-term investments, while operating cash flow has alternated between positive and negative periods despite recurring capital expenditure. Product concentration and substantial research, selling, and administrative costs create operating leverage in either direction: delayed deliveries can leave the expense base exposed, while favorable volume and mix can lift profitability.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $118.20M Sep 30, 2026
- Previous quarter · operating cash flow
- −$77.40M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $118.20M | −$21.50M |
| Jun 30, 2026 | −$77.40M | −$28.80M |
| Mar 31, 2026 | $71.20M | −$24.20M |
| Dec 31, 2025 | $229.80M | −$22.60M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Bruker (BRKR)?
Short answer · as of
The next earnings report is expected on Feb 11, 2027.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Semiconductor deliveries are the immediate checkpoint. Compare the scheduled earnings release with management’s expectation that shifted revenue returns alongside better volume, mix, organic growth, operating margin, and earnings.
Beyond sales, watch for operating cash flow to recover, losses to reverse, and cash to strengthen relative to debt. Longer-range analyst estimates assume continued revenue and earnings expansion, but firm ratings remain dispersed; Bruker’s own cash conversion and margin progression provide the more useful test.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We expect fourth quarter organic revenue to grow in the lower mid-single digits percentage year over year.
Gerald Herman ·
We expect meaningful sequential and year-over-year increases in operating margin and EPS due to higher volume and favorable mix in the fourth quarter, as well as due to the compounding effects from our cost-saving actions.
Gerald Herman ·
How does Bruker compare with its peers?
Short answer
Bruker's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Bruker differs from a typical medical-device peer because its portfolio spans mass spectrometry, microbiology identification, X-ray and atomic-force microscopy, semiconductor metrology, multi-omics tools, and superconducting materials. Customers are buying research, analytical, diagnostic, and industrial capability, not mainly patient-facing devices.
The economic profile remains that of a product-led instrument supplier: product revenue dominates, while a smaller combined category covers other products and services. That mix leaves Bruker more exposed to shipment timing and hardware mix than a service-led business, even though diagnostics and specialized services broaden its demand sources.
| Company | Price | Market value | Score |
|---|---|---|---|
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $70.53 Nov 18, 2026 | $9.34B | 94 5-pillar Nov 18, 2026 | |
| $320.00 Nov 19, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $94.54 Nov 18, 2026 | $5.21B | 88 5-pillar Nov 18, 2026 | |
| $68.34 Nov 18, 2026 | $13.6B | 87 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $546.72 Nov 18, 2026 | $7.09B | 85 5-pillar Nov 18, 2026 | |
| $139.98 Nov 18, 2026 | $9.71B | 85 5-pillar Nov 18, 2026 | |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $103.32 Nov 18, 2026 | $19.6B | 79 5-pillar Nov 18, 2026 | |
| Bruker (BRKR) — this page | $62.10 | $9.48B | 59 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $50.00 – $80.00
- Consensus target
- $67.00
- Median target
- $70.00
Consensus record · Captured .
Measured against a quoted price of $62.10 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 15, 2026
- Transactions
- 38
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 5
- Other transactions
- 33
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 89.5% Period end Sep 30, 2026
- Previous quarter · ownership
- 94.4% Prior to period end Sep 30, 2026
- Reporting holders
- 449 Period end Sep 30, 2026
- Previous quarter · holders
- 435 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 20,296,294 |
| Orbis Allan Gray Ltd | 17,940,076 |
| Blackrock, INC. | 11,789,436 |
| Pallas Capital Advisors LLC | 9,483,840 |
| Vanguard Portfolio Management LLC | 4,974,922 |
Tracked investors
Which of the 16 named investors we follow held BRKR in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.14% | $31.59M | Added +1052.3% shares |
| Viking Global | Andreas Halvorsen | Q3 2026 | 0% | $0 | Sold out (was $53.77M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Bruker (BRKR)?
Bruker Healthcare Stock: Key Questions Answered
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered); the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
What does the MALDI Biotyper add to Bruker’s business mix?
The MALDI Biotyper gives Bruker exposure to rapid pathogen identification within a portfolio otherwise rich in research and analytical instruments. Microbiology diagnostics therefore contribute a distinct demand stream without making Bruker a conventional patient-device company.
Why do semiconductor delivery requirements move Bruker revenue?
Bruker sells metrology and defect-detection equipment whose reported revenue can depend on customer delivery timing. Management said semiconductor requirements shifted planned sales between reporting periods, with related effects on expected margins and earnings.
Why has Bruker’s rising revenue not produced stronger profit?
Research, selling, and administrative costs remain substantial, and recent gross profit did not prevent operating and net losses. Cash generation has also been uneven, showing that higher sales have not consistently converted into profit or cash.
How does Bruker Energy and Supercon Technologies change the company’s exposure?
The segment adds superconducting materials, devices, and beamline or synchrotron instrumentation to the life-science and nanoscale portfolio. This introduces advanced-research and energy-related demand that a medical-device label would not imply.
What is the BRKR stock price today?
The last price recorded for Bruker Corporation (BRKR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BRKR price target?
The analyst consensus price target for Bruker Corporation (BRKR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does BRKR pay a dividend?
Yes. The dividend yield of Bruker Corporation (BRKR) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 82 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 3 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com